When Mimi Reed, age 87, was diagnosed with uterine cancer, her main goal was to maintain her independence. Read the story to learn how Ramy Sedhom, MD, at Penn Medicine Princeton Cancer Center, was able to help her do just that.
PLAINSBORO, N.J. – The Penn Medicine Princeton Cancer Center received a $2.5 million grant from the Bristol Myers Squibb Foundation to help fund an innovative program to ensure holistic, patient-centered care for older adults with cancer.
The new Geriatric Oncology Program will transform cancer treatment and supportive care for older adults by expanding research opportunities, enhancing professionals’ expertise in geriatrics, and increasing outreach to seniors in the central New Jersey community.
“We serve a dynamic population that is aging and experiences higher cancer rates than the national average, and all of them deserve the very best, most personalized care we can offer,” said James Demetriades, CEO of Penn Medicine Princeton Health. “We see a significant and growing need for specialized cancer care for older adults. Today, 70 percent of our patients with cancer are 65 or older, and 18 percent are at least 80 years old. Every one of those individuals faces unique challenges, and we are committed to working with them to develop care plans that meet their unique needs.”
The Geriatric Oncology Program at Princeton Health will be led by Ramy Sedhom, MD, a clinical assistant professor of Hematology-Oncology in the Perelman School of Medicine at University of Pennsylvania. Sedhom is co-leader of the Geriatric Oncology service line across the Penn Medicine system, a faculty member at the Penn Center for Cancer Care Innovation (PC3I) of the Abramson Cancer Center, and a representative on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline Committee for Older Adult Oncology.
“Our program is rooted in the proposition of caring for the whole patient, not their disease,” Sedhom said. “There is a core tenant in geriatrics — you don’t know what you don’t know. Older adults are a distinct group with unique personal and caregiver needs. We are fortunate to receive support from the Bristol Myers Squibb Foundation to transform the cancer care of older adults in our community.”
As part of the program, patients aged 80 and older will undergo a geriatric assessment to evaluate their health condition, as well as social, cultural, spiritual, financial, and emotional factors.
Historically, older adults have not been well-represented in clinical trials, which poses a challenge for oncologists attempting to match the latest treatments with this population and results in health equity gaps in geriatric oncology care. Initiatives driven by the new Geriatric Oncology Program aim to change this.
"The Bristol Myers Squibb Foundation's focus on heath equity has a goal to empower and scale new ideas with the potential to improve and flourish," said John Damonti, president of the Bristol Myers Squibb Foundation. “In that spirit, we are proud to support the creation of a geriatric oncology program at Penn Medicine Princeton Health. This new program will provide comprehensive, personalized care to people over 65, who face particular needs that can often be overlooked. It will also fund innovative research, infrastructure development, education and outreach to expand the reach and impact of this work.''
The grant will support the Geriatric Oncology Program’s efforts to build a research infrastructure to design and implement clinical trials to improve the care of older adults with cancer. It will also bolster an array of other crucial activities, such as:
- Recruiting multidisciplinary teams of professionals with expertise in geriatrics, including clinicians, supportive care staff, and community health navigators.
- Testing new treatments and care delivery models by bringing new research from Penn Medicine’s Abramson Cancer Center to patients in central New Jersey.
- Expanding geriatric competencies of Princeton Health staff through education and increasing outreach to seniors through community health navigators.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.